We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IINN:NASDAQInspira Technologies Oxy B.H.N. Ltd. Analysis

Data as of 2026-06-18 - not real-time

$0.38

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Inspira Technologies (IINN) is trading at $0.38, barely above its 52‑week low of $0.283, with the 20‑day SMA (≈1.51) far above the current price, indicating a steep downtrend. The RSI sits near 49, suggesting the stock is neither oversold nor overbought, while the MACD histogram is negative and the signal line is labeled “bearish,” reinforcing short‑term weakness. Volatility is extreme at roughly 400% over 30 days and beta is high (≈2.86), pointing to amplified market swings. Fundamentals are weak: operating margin is –47%, EBITDA and cash flows are deeply negative, and the company posts a trailing EPS of –$0.45 with a forward EPS of –$0.70. The price‑to‑book ratio of 5.85 and price‑to‑sales of 57x are far above industry averages, implying the market is pricing in speculative upside despite the lack of earnings. News notes a second‑quarter EPS of –$0.32 in line with expectations, and a recent announcement of a strategic focus under a new Nasdaq ticker, but no concrete revenue growth materializes. Overall, the stock reflects extreme greed sentiment (Fear & Greed Index 88.5) while bearing a massive historical drawdown of over 80%, making it a high‑risk play with limited upside unless a dramatic turnaround occurs.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Bearish MACD and negative histogram
  • Decreasing volume trend
  • Extreme volatility and high beta

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential strategic shift with new ticker
  • Support level near $0.283 offering limited downside
  • Continued negative cash flow and earnings

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained operating losses and negative margins
  • High valuation multiples relative to fundamentals
  • Regulatory and execution risk in medical‑device market

Key Metrics & Analysis

Financial Health

P/E Ratio-0.5
ROE-397.89%
ROA-126.98%
Debt/Equity20.66
P/B Ratio5.8
Op. Cash Flow$-9861000
Free Cash Flow$-5668375
Industry P/E24.3

Technical Analysis

TrendNeutral
RSI48.6
Support$0.28
Resistance$3.85
MA 20$1.51
MA 50$0.89
MA 200$0.91
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Target Price$5.00
Upside/Downside1215.79%
GradeOvervalued
TypeValue

Risk Assessment

Beta2.86
Volatility399.24%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.